Pipeline

May 10, 2021

Company	Drug/Device	Medical Condition	Status
COVID-19 Trials and Actions
HDT Bio Gennova Biopharmaceuticals	RNA-based COVID-19 vaccine	COVID-19	first patient dosed in phase 1/2 trial in India
Adagio Therapeutics	ADG20 vaccine	COVID-19	phase 2/3 trial initiated
Novavax	NVX-CoV2373 vaccine	COVID-10 in patients age 12 to 17	pediatric expansion of phase 3 clinical trial initiated
Other Trials and Actions
Genascence	GNSC-001	osteoarthritis	dosing of all patients in phase 1 trial complete
Neoleukin Therapeutics	NL-201	advanced solid tumors	phase 1 trial initiated
NervGen Pharma	NVG-291	nerve damage	first patient dosed in phase 1 trial
Vivace Therapeutics	VT3989	refractory metastatic solid tumors	first patient dosed in phase 1 trial in the U.S. and Australia
Repare Therapeutics	RP-6306	PKMYT1 inhibitor-sensitive cancers	first patient dosed in phase 1 trial
Landos Biopharma	NX-13	ulcerative colitis	first patient dosed in phase 1b trial
Vaxart	oral tablet norovirus vaccine	norovirus	first patient enrolled in phase 1b boosting regimen trial
Cerecor	CERC-007	adult-onset Still’s disease	first patient dosed in phase 1b trial
Treadwell Therapeutics	CFI-400945	PLK4 inhibitor in patients with leukemia	first patient dosed in phase 1b/2 trial
Merus	MCLA-129	advanced lung cancer and other solid tumors	first patient treated in phase 1/2 clinical trial
Peptomyc	OMO-103 lead compound	advanced solid tumors	first patient dosed in phase 1/2 trial
Carmot Therapeutics	CT-868	treatment of overweight and obese patients with Type 2 diabetes	IND for a phase 2 trial granted by the FDA
City of Hope	mushroom powder tablets	prostate-specific antigen levels	recruiting begun in phase 2 trial
Tessa Therapeutics	autologous CD30 CAR-T in relapsed/refractory cHL	relapsed or refractory Hodgkins lymphoma	enrollment of 12-patient cohort complete in phase 2 trial
Galmed Pharmaceuticals	Aramchol	nonalcoholic steatohepatitis and fibrosis	IND for phase 3 trial granted by China’s National Medical Products Administration
Catalyst Biosciences	MarzAA	hemophilia A or B with inhibitors	first patient dosed in phase 3 trial
Isofol Medical	Arfolitixorin	first-line metastatic colorectal cancer	recruiting complete in global phase 3 trial
ObSeva	Yslty	moderate-to-severe endometriosis-associated pain	enrollment complete in phase 3 trial
Praxis Precision Medicines	PRAX-562	SCN2A development and epileptic encephalopathy	Orphan Drug designation granted by the FDA
Cerapedics	P-15L	bone graft in cases of degenerative disc disease	Breakthrough Device designation awarded by the FDA
AstraZeneca	Farxiga (dapagliflozin) oral tablets	kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression	approved by the FDA
Chiesi Global Rare Diseases	Ferriprox (deferiprone)	transfusional iron overload caused by sickle cell disease or other anemias in adults and children ages three years and older	approved by the FDA
Merck	Keytruda in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy	locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma	approved by the FDA